

Ref: UHB 17-200

**NHS Foundation Trust** 

## **Freedom of Information Request**

Date 10 April 2017

Dear

Thank you for your request for information under the Freedom of Information Act 2000. The Trusts response is as follows:

Number of patients treated	Abatacept [Orencia]	Adalimumab [Humira]	Apremilast [Otezla]	Certolizumab [Cimzia]	Etanercept [Enbrel]	Etanercept Biosimilar	Golimumab [Simponi]	Infliximab [Remicade]	Infliximab Biosimilar	Rituximab [Mabthera]	Secukinumab [Cosentyx]	Tocilizumab [Ro Actemra]
Rheumatoi d Arthritis	44 (41)	76 (67)	0	10 (10)	98 (30)	34 (59)	16 (11)	14 (6)	9 (10)	25 (32)	0	30 (28)
Ankylosing Spondylitis	0	26 (25)	0	0	11 (6)	4 (7)	8 (7)	2 (1)	2(1)	0	0	0
Psoriatic Arthritis	0	28 (28)	0	0	20 (10)	8 (15)	20 (17)	4 (2)	6 (5)	0	0	0

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Trust Secretary
University Hospitals Bristol NHS Foundation Trust
Trust Headquarters
Marlborough Street
Bristol
BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

To view the Freedom of Information Act in full please click <a href="here.">here.</a>

Yours sincerely,